Two medicines, side by side
Celecoxib vs tramadol
Celecoxib and tramadol are both labeled for pain. Drugs@FDA records approvals of celecoxib since 1998 and of tramadol since 1995. Pharmacies paid $0.0762 per celecoxib 200 mg capsule and $0.0248 per tramadol HCl 50 mg tablet (NADAC, October 7, 2026); the strengths differ, so the two prices are not like for like. In FDA's classes, celecoxib is a nonsteroidal anti-inflammatory drug and tramadol an opioid agonist.
Check it at the source: the celecoxib FDA label on DailyMed (effective November 22, 2024); the tramadol FDA label on DailyMed (effective March 5, 2026).
Highlights of the celecoxib record
Celecoxib (Celebrex) · label of November 22, 2024
RISK OF SERIOUS CARDIOVASCULAR AND GASTROINTESTINAL EVENTS Cardiovascular Thrombotic Events
Nonsteroidal anti-inflammatory drugs (NSAIDs) cause an increased risk of serious cardiovascular thrombotic events, including myocardial infarction, and stroke, which can be fatal. This risk may occur early in the treatment and may increase with duration of use [see Warnings and Precautions (5.1) ].
Used for
From the label: indicationsCELEBREX is a nonsteroidal anti-inflammatory drug indicated for: • Osteoarthritis (OA) ( 1.1 ) • Rheumatoid Arthritis (RA) ( 1.2 ) • Juvenile Rheumatoid Arthritis (JRA) in patients 2 years and older ( 1.3 ) • Ankylosing Spondylitis (AS) ( 1.4 ) • Acute Pain (AP) ( 1.5 ) • Primary Dysmenorrhea (PD) ( 1.6 ) 1.1 Osteoarthritis (OA) For the management of the signs and symptoms of OA [see Clinical Studies (14.1) ]. 1.2 […]
On the market
- Earliest approval on file
- December 31, 1998
- Generic labelers
- 63 labelers
- Pharmacy cost
- $0.0762 per capsule
Supply and safety
- Shortage
- No current entry
- Recalls
- 2
Highlights of the tramadol record
Tramadol (Ultram) · label of March 5, 2026
SERIOUS AND LIFE-THREATENING RISKS FROM USE OF TRAMADOL HYDROCHLORIDE EXTENDED-RELEASE TABLETS Addiction, Abuse, and Misuse Because the use of Tramadol hydrochloride extended-release tablet exposes patients and other users to the risks of opioid addiction, abuse, and misuse, which can lead to overdose and death, assess each patient's risk prior to prescribing and reassess all patients regularly for the development of these behaviors and conditions [see Warnings and Precautions ( 5.1 )].
Used for
From the label: indicationsTramadol hydrochloride extended-release tablet is indicated for the management of severe and persistent pain that requires an opioid analgesic and that cannot be adequately treated with alternative options, including immediate-release opioids. […]
On the market
- Earliest approval on file
- March 3, 1995
- Generic labelers
- 39 labelers
- Pharmacy cost
- $0.0248 per tablet
Supply and safety
- Shortage
- No current entry
- Recalls
- 8
Source: FDA drug labels via openFDA (Celecoxib label of November 22, 2024, Tramadol label of March 5, 2026); NDC Directory, Drugs@FDA, NADAC, FDA shortages and recalls (October 8, 2026)
How do celecoxib and tramadol differ on the record?
In FDA's classes, celecoxib is a nonsteroidal anti-inflammatory drug and tramadol an opioid agonist.
How each works, in its label's words: Celecoxib, “The mechanism of action of CELEBREX is believed to be due to inhibition of prostaglandin synthesis, primarily via inhibition of COX-2.”; Tramadol, “Tramadol hydrochloride extended-release tablet contains tramadol, an opioid agonist and an inhibitor of reuptake of norepinephrine and serotonin.”
Both labels carry a boxed warning; the records quote them.
Generics: celecoxib since 2014; tramadol since 2002 (Drugs@FDA).
DEA schedule: celecoxib none; tramadol CIV.
| Celecoxib | Tramadol | |
|---|---|---|
| Labeled for | Osteoarthritis, Rheumatoid arthritis, Pain, Migraine | Pain |
| Pharmacologic class | Nonsteroidal Anti-inflammatory Drug | Opioid Agonist |
| How it works (label) | Celecoxib has analgesic, anti-inflammatory, and antipyretic properties. The mechanism of action of CELEBREX is believed to be due to inhibition of prostaglandin synthesis, primarily via inhibition of COX-2. | Tramadol hydrochloride extended-release tablet contains tramadol, an opioid agonist and an inhibitor of reuptake of norepinephrine and serotonin. |
| Half-life (label) | It is primarily metabolized by CYP2C9 with a half-life of approximately 11 hours. | n/a |
| Earliest approval on file (Drugs@FDA) | December 31, 1998 | March 3, 1995 |
| First generic approved | May 30, 2014 | June 19, 2002 |
| Generic labelers (NDC) | 63 labelers | 39 labelers |
| Pharmacy cost (NADAC, each one's most listed form; strengths differ) | $0.0762 per capsule (Celecoxib 200 mg capsule) | $0.0248 per tablet (Tramadol HCl 50 mg tablet) |
| 12-month price change | -13% | -1% |
| Boxed warning | Yes | Yes |
| Shortage now | No current entry | No current entry |
| Recalls recorded | 2 | 8 |
| FAERS reports (a report is not proof of cause; counts follow how widely a medicine is used) | 130,882 | 37,421 |
| DEA schedule | none | CIV |
Source: Drugs@FDA, FDA NDC Directory, CMS NADAC of October 7, 2026, FDA shortages and recalls, FAERS via openFDA (FDA files October 8, 2026)
What do the labels say about using others of their kind?
Celecoxib label, drug interactionsConcomitant use of Celecoxib with other NSAIDs or salicylates (e.g., diflunisal, salsalate) increases the risk of GI toxicity, with little or no increase in efficacy [see Warnings and Precautions (5.2) ].
Tramadol label, warnings and precautionsRisks from Concomitant Use with Benzodiazepines or Other CNS Depressants Profound sedation, respiratory depression, coma, and death may result from the concomitant use of tramadol hydrochloride extended-release tablets with benzodiazepines and/or other CNS depressants, including alcohol (e.g., non-benzodiazepine sedatives/hypnotics, anxiolytics, tranquilizers, muscle relaxants, general anesthetics, antipsychotics …
Source: FDA drug labels via openFDA
What next?
- Alternatives to celecoxib
- every medicine labeled for the same conditions